Abstract
Methylation alterations of specific genes have recently been identified as diagnostic biomarkers for human cancers. Although MEG3 has been proved to be a tumor suppressor in cervical cancer according to our previous study, the diagnostic value of MEG3 methylation in plasma is still unknown. Therefore, the aim of this study is to identify a novel epigenetic biomarker for cervical cancer. In the current study, the level of MEG3 methylation was evaluated using methylation-specific polymerase chain reaction. The results showed that the level of MEG3 methylation was significantly higher in cervical cancer tissues and patients’ plasmas than those in adjacent normal tissues and plasmas of healthy participants respectively. Moreover, the accuracy was good enough for MEG3 methylation in plasma to discriminate CIN III patients from healthy participants. In addition, MEG3 methylation in plasma also has high discriminating power to predict HR-HPV infection and lymph node metastasis. Furthermore, hypermethylation of MEG3 in plasma was associated with worse recurrence-free and overall survival in cervical cancer patients. In conclusions, MEG3 methylation in plasma can serve as a diagnostic and prognostic biomarker for cervical cancer, providing useful information for clinical management.
Highlights
In present study, we mainly focused on the diagnostic value of MEG3 methylation in plasma base on our previous study
The statistical analysis showed that plasmas of cervical cancer patients expressed a significantly higher level of MEG3 methylation than that of healthy participants (Fig. 1d, Table 1)
Aberrant DNA methylation, which is the most common epigenetic change in human malignancies, may be used as a diagnosis, surveillance and prognostic biomarker according to recent studies[14,15,16]
Summary
We mainly focused on the diagnostic value of MEG3 methylation in plasma base on our previous study. We first confirmed the reliability of MEG3 methylation in plasma of cervical cancer patients. We found that MEG3 methylation in plasma was an effective biomarker for the diagnosis of CIN III (cervical intraepithelial neoplasia), HR-HPV (High risk-Human papillomavirus) infection and lymph node metastasis. We demonstrated that MEG3 methylation in plasma was a prognostic factor for cervical cancer patients. Together, these results were to identify the clinical significance of plasma MEG3 methylation in cervical cancer
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
